National Comprehensive Cancer Network



About NCCN

NCCN Updates Antiemesis Guidelines

JENKINTOWN, Pa., January 8, 2007 —The National Comprehensive Cancer Network (NCCN) is pleased to announce updates to the NCCN Antiemesis Guidelines. The NCCN Clinical Practice Guidelines in Oncology™ are used extensively by managed care companies and by Medicare as the basis for coverage policies.

The guidelines have a new recommendation for breakthrough treatment for chemotherapy-induced nausea/vomiting. Nabilone (Cesamet, Valeant) is now recommended for breakthrough treatment.

The guidelines table describing the emetogenic potential of different antineoplastic agents has been revised. Bortezomib (Velcade, Millennium), dasatinib (Sprycel, Bristol Myers-Squibb), decitabine (Dacogen, MGI Pharma), lenalidomide (Revlimid, Celgene), nelarabine (Arranon, GlaxoSmithKline), sorafenib (Nexavar, Bayer Pharmaceuticals), sunitinib (Sutent, Pfizer), thalidomide (Thalomid, Celgene), and trastuzumab (Herceptin, Genentech) are all now considered to have minimal emetic risk.

Metoclopramide (Reglan, Baxter) and diphenhydramine (Benadryl, Parke Davis) are no longer recommended for delayed emesis prevention for patients receiving moderate-emetic-risk chemotherapy.

NCCN Clinical Practice Guidelines in OncologyTM are developed and updated through a consensus-driven process with explicit review of the scientific evidence by multidisciplinary panels of expert physicians from NCCN member institutions. The most recent version of this and all the guidelines are available free of charge at www.nccn.org.

About the National Comprehensive Cancer Network

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 23 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives. For more information, visit NCCN.org.

The NCCN Member Institutions are:

  • City of Hope Comprehensive Cancer Center
  • Dana-Farber/Brigham and Women's Cancer Center
    Massachusetts General Hospital Cancer Center
  • Duke Cancer Institute
  • Fox Chase Cancer Center
  • Huntsman Cancer Institute at the University of Utah
  • Fred Hutchinson Cancer Research Center / Seattle Cancer Care Alliance
  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University
  • Memorial Sloan-Kettering Cancer Center
  • Moffitt Cancer Center
  • The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
  • Roswell Park Cancer Institute
  • Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
  • St. Jude Children's Research Hospital/The University of Tennessee Health Science Center
  • Stanford Cancer Institute
  • University of Alabama at Birmingham Comprehensive Cancer Center
  • UC San Diego Moores Cancer Center
  • UCSF Helen Diller Family Comprehensive Cancer Center
  • University of Colorado Cancer Center
  • University of Michigan Comprehensive Cancer Center
  • UNMC Eppley Cancer Center at The Nebraska Medical Center
  • The University of Texas MD Anderson Cancer Center
  • Vanderbilt-Ingram Cancer Center

Quick Links


About NCCN| NCCN Member Institutions| Patient Resources| NCCN Foundation| Privacy Policy| Legal Notices| Contact Us

275 Commerce Drive, Suite 300, Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0260
Copyright © 2012 National Comprehensive Cancer Network, All Rights Reserved